Olaparib

Overview

Olaparib is a potent oral PARP inhibitor with anti-tumor activity, specifically designed to exploit the DNA-repair pathway deficiencies in cancer cells. It is primarily used for the treatment of ovarian, breast, and certain other types of cancer linked to BRCA mutations.

API suppliers (19)

Suppliers of Olaparib evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.

• HUADONG MEDICINE (XI'AN) BODYGUARD PHARMACEUTICAL CO LTD2 active DMF
• ALP PHARM BEIJING CO LTD1 active DMF
• SCINOPHARM TAIWAN LTDTaiwan1 active DMF
• MSN Laboratories Private LimitedIndia1 active DMF GMP on record
• Hetero Labs LimitedIndia1 active DMF GMP on record
• Wisdom Pharmaceutical Co., LtdChina1 active DMF
• Cipla USA, Inc.USA1 active DMF
• ALIVUS LIFE SCIENCES LTDIndia1 active DMF GMP on record
• Shandong Anhong Pharmaceutical Co., Ltd.China1 active DMF GMP on record
• CAMBREX PROFARMACO MILANO SRLItaly1 active DMF GMP on record
• Sichuan Kelun Pharmaceutical Co., Ltd.China1 active DMF
• Biocon LimitedIndia1 active DMF
• Zhejiang Ausun Pharmaceutical Co., Ltd.China1 active DMF GMP on record
• Intas Pharmaceuticals Ltd.India1 active DMF GMP on record
• BDR LIFESCIENCES PRIVATE LIMITEDIndia1 active DMF GMP on record
• Deva Holding As1 active DMF GMP on record
• BIOPHORE INDIA PHARMACEUTICALS PVT LTD1 active DMF
• Alembic Pharmaceuticals LimitedIndia1 active DMF GMP on record
• DR REDDYS LABORATORIES LTD1 active DMF GMP on record

Patent & exclusivity (US)

Per the FDA Orange Book (2 approved US products), the latest listed US patent on Olaparib expires 25 Oct 2041 and exclusivity 8 May 2027. Generic API sourcing typically opens up once these lapse.

Therapeutic areas